http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9633976-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c24684033fba97d1ad845ce453a57e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b898fd7758e6b246fcfc7fb0168ab501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_85c3fe5bac3466c915deb647c828df98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_674007c71b9224ea94c4d1b4d9936a8b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae1ac00590ab5cd1e5572c51bd6aed53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_636684101b3b4dcec718fc737504ec08 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-76 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-74 |
| filingDate | 1996-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68809cc3ac7293a8daad1df5e6126563 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac8a4b690d774eba281d176701e0a8ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca76fa4e3c4a628e503c599e8478f174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7154043f8518fe7e659011cee1c3b62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ad4cd60ad45d1f9dcc9ed4ab24f6765 |
| publicationDate | 1996-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9633976-A1 |
| titleOfInvention | Hydantoine derivatives as intermediate products for active pharmaceutical agents |
| abstract | The present invention concerns hydantoine derivatives of general formula (I) in which: R stands for cyano, C(=NH)-O-(C1-C6)-alkyl, C(=NH)-NH-X, CH2-NH-X, or NH-X1; X stands for hydrogen, (C¿1?-C6) alkyl, (C1-C6) alkylcarbonyl, (C1-C6)-alkoxycarbonyl, (C1-C18)-alkylcarbonyloxy-(C1-C6)-alkoxycarbonyl, optionally substituted (C6-C14)-arylcarbonyl, optionally substituted (C6-C14)-aryloxycarbonyl, (C6-C14)-aryl-(C1-C6)-alkoxycarbonyl which can also be substituted in the aryl group, (R?5O)¿2P(O), cyano, hydroxy, (C1-C6)-alkoxy, (C6-C14)-aryl-(C1-C6)-alkoxy which can also be substituted in the aryl group, or amino; X1 has one of the meanings of X or stands for R'-NH-C(=N-R'), R' and R' independently of one another having one of the meanings of X; R1 stands for (C¿1?-C8)-alkyl, C6-C14)-aryl-(C1-C8)-alkyl optionally substituted in the aryl group, or (C3-C8)-cycloalkyl; R?2¿ stands for hydrogen, (C¿1?-C8)-alkyl, optionally substituted (C6-C14)-aryl, (C6-C14)-aryl-(C1-C8)-alkyl optionally substituted in the aryl group or (C3-C8)-cycloalkyl; R?3¿ stands for hydrogen or CH¿2?-CO-OR?4; R4¿ stands for hydrogen, (C¿1?-C6)-alkyl, (C6-C14)-aryl-(C1-C6)-alkyl optionally substituted in the aryl group, or optionally substituted (C6-C14)-aryl; R?5¿ stands for hydrogen, (C¿1?-C8)-alkyl, optionally substituted (C6-C14)-aryl or (C6-C14)-aryl-(C1-C8)-alkyl which can also be substituted in the aryl group. The follwing other conditions also apply; if R?3¿ stands for hydrogen, R may not stand for CN, NH¿2? or CH2-NH2: if the compounds of general formula (I) are present in racemic form with respect to the asymmetric centre in the hydantoine ring and R?3¿ stands for methoxycarbonyl methyl, R1 for methyl and R2 for hydrogen or methyl, R may not stand for CN or C(=NH)-OC¿2?H5; and if the compounds of general formula (I) are present in racemic form with respect to asymmetric centre in the hydantoine ring and R?3¿ standssfor methoxycarbonyl methyl or hydroxycarbonyl methyl, R1 for methyl and R2 for hydrogen or methyl, R may not stand for NH¿2?, CH2-NH2, C(=NH)-NH2, tert-butyloxycarbonylaminomethyl or benzyloxycarbonylguanidino. The invention also concerns the salts of the said hydantoine derivatives. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6759424-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6680333-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0816343-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-717106-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6667334-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6962937-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6034238-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6294562-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6018053-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0811616-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6838439-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6794517-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02072557-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6521654-B2 |
| priorityDate | 1995-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 348.